Compare Bandwidth Inc (BAND) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bandwidth Inc vs Crispr Therapeutics AG — how do they compare? Bandwidth Inc trades at $51.42 (market cap $1.66B), while Crispr Therapeutics AG trades at $53.95 (market cap $5.23B). The key difference: Crispr Therapeutics AG is far larger — about 3.2× Bandwidth Inc's market cap, and Bandwidth Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| BAND | CRSP | |
|---|---|---|
Market Cap | $1.66B | $5.23B |
Sector | Technology | Health |
52-Week High | $78.44 | $76.78 |
52-Week Low | $12.82 | $44.34 |
Enterprise Value | $2.04B | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bandwidth (BAND) trades at $52.30, down 0.78% on the day, with strong technical momentum showing bullish moving averages but overbought RSI signals. The company demonstrated solid Q2 2026 performance with EPS of $0.37 beating estimates and 22% revenue growth, driven by AI-driven communications demand and enterprise wins. Analyst sentiment remains overwhelmingly positive with 75% buy ratings and a $75.25 consensus price target representing 44% upside potential.
The outlook appears favorable with accelerating AI adoption and raised 2026 guidance, though valuation remains elevated at 34x EBITDA. Key risks include execution challenges in scaling AI deployments and competitive pressure in cloud communications. Current profitability metrics show improvement but remain thin, requiring sustained growth to justify premium multiples.
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bandwidth Inc
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
